ARWR · Arrowhead Pharmaceuticals, Inc. · Debt

$57.48 -1.36 (-2.32%)

Market Cap

$8.46B

141.25M

Volume · Oct 22 222.3K Avg daily vol (3M) 1.87M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Convertible debt, including current maturities	2026-06-30	USD 682,700,000	10-Q filed 2026-08-04
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Noncurrent convertible debt USD 682,707,000
Line of credit borrowings, including current maturities	2026-06-30	USD 181,400,000	10-Q filed 2026-08-04
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of line of credit borrowings USD 40,000,000 Noncurrent line of credit borrowings USD 141,366,000
Operating lease liabilities	2026-06-30	USD 119,620,000	10-Q filed 2026-08-04
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 5,322,000 Noncurrent operating lease liabilities USD 114,298,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 879407 CUSIP 04280A100 13F (30d) 59 filings 59 filers Visit website Investor relations